Jian-Ying Zhang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10561496/publications.pdf

Version: 2024-02-01

		159585	149698
78	3,418	30	56
papers	citations	h-index	g-index

81	81	81	3820
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Effect of Cerium Oxide Nanoparticles on Rice: A Study Involving the Antioxidant Defense System and In Vivo Fluorescence Imaging. Environmental Science & Technology, 2013, 47, 5635-5642.	10.0	289
2	Stress Response and Tolerance of Zea mays to CeO₂ Nanoparticles: Cross Talk among H₂O₂, Heat Shock Protein, and Lipid Peroxidation. ACS Nano, 2012, 6, 9615-9622.	14.6	254
3	A Novel Cytoplasmic Protein with RNA-binding Motifs Is an Autoantigen in Human Hepatocellular Carcinoma. Journal of Experimental Medicine, 1999, 189, 1101-1110.	8.5	191
4	Competing endogenous RNA networks and gastric cancer. World Journal of Gastroenterology, 2015, 21, 11680.	3.3	161
5	Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clinical Cancer Research, 2003, 9, 5120-6.	7.0	128
6	Using Proteomic Approach to Identify Tumor-Associated Proteins as Biomarkers in Human Esophageal Squamous Cell Carcinoma. Journal of Proteome Research, 2011, 10, 2863-2872.	3.7	122
7	Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiology Biomarkers and Prevention, 2003, 12, 136-43.	2.5	122
8	Glycine, serine and threonine metabolism confounds efficacy of complement-mediated killing. Nature Communications, 2019, 10, 3325.	12.8	118
9	The effect of quercetin nanoparticle on cervical cancer progression by inducing apoptosis, autophagy and anti-proliferation via JAK2 suppression. Biomedicine and Pharmacotherapy, 2016, 82, 595-605.	5.6	98
10	Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma. Journal of Hepatology, 2007, 46, 107-114.	3.7	93
11	Aberrant Expression of Fetal RNA-Binding Protein p62 in Liver Cancer and Liver Cirrhosis. American Journal of Pathology, 2001, 159, 945-953.	3.8	92
12	Autoantibodies to tumor-associated antigens as diagnostic biomarkers in hepatocellular carcinoma and other solid tumors. Expert Review of Molecular Diagnostics, 2010, 10, 321-328.	3.1	74
13	Using Proteomic Approach to Identify Tumor-Associated Antigens as Markers in Hepatocellular Carcinoma. Journal of Proteome Research, 2008, 7, 4004-4012.	3.7	65
14	Autoantibodies against tumor-associated antigens in the early detection of lung cancer. Lung Cancer, 2016, 99, 172-179.	2.0	62
15	Autoantibodies to tumor-associated antigens as biomarkers in cancer immunodiagnosis. Autoimmunity Reviews, 2011, 10, 331-335.	5.8	61
16	Autoimmune Responses to mRNA Binding Proteins p62 and Koc in Diverse Malignancies. Clinical Immunology, 2001, 100, 149-156.	3.2	60
17	Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies. Oncology Reports, 2006, 16, 1105-10.	2.6	60
18	Preferential humoral immune response in prostate cancer to cellular proteins p90 and p62 in a panel of tumor-associated antigens. Prostate, 2005, 63, 252-258.	2.3	55

#	Article	IF	Citations
19	Autoantibodies to tumor-associated antigens combined with abnormal alpha-fetoprotein enhance immunodiagnosis of hepatocellular carcinoma. Cancer Letters, 2010, 289, 32-39.	7.2	52
20	Using immunomic approach to enhance tumor-associated autoantibody detection in diagnosis of hepatocellular carcinoma. Clinical Immunology, 2014, 152, 127-139.	3.2	46
21	Autoimmune response to anti-apoptotic protein survivin and its association with antibodies to p53 and c-myc in cancer detection. Cancer Detection and Prevention, 2005, 29, 241-248.	2.1	45
22	Identification of autoantibodies to ECH1 and HNRNPA2B1 as potential biomarkers in the early detection of lung cancer. OncoImmunology, 2017, 6, e1310359.	4.6	43
23	Tumor-associated antigen arrays to enhance antibody detection for cancer diagnosis. Cancer Detection and Prevention, 2004, 28, 114-118.	2.1	42
24	Using Immunoproteomics to Identify Alpha-enolase as an Autoantigen in Liver Fibrosis. Journal of Proteome Research, 2013, 12, 1789-1796.	3.7	42
25	Using immunoproteomics to identify tumor-associated antigens (TAAs) as biomarkers in cancer immunodiagnosis. Autoimmunity Reviews, 2013, 12, 1123-1128.	5.8	41
26	Long Noncoding RNA HOST2 Promotes Epithelial-Mesenchymal Transition, Proliferation, Invasion and Migration of Hepatocellular Carcinoma Cells by Activating the JAK2-STAT3 Signaling Pathway. Cellular Physiology and Biochemistry, 2018, 51, 301-314.	1.6	32
27	p62/IMP2 stimulates cell migration and reduces cell adhesion in breast cancer. Oncotarget, 2015, 6, 32656-32668.	1.8	32
28	Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and serves as a leukemiaâ€associated antigen associated with autoantibody response in a subset of patients. European Journal of Haematology, 2007, 79, 210-225.	2.2	31
29	Autoimmune response to PARP and BRCA1/BRCA2 in cancer. Oncotarget, 2015, 6, 11575-11584.	1.8	31
30	Tumor associated antigens or anti-TAA autoantibodies as biomarkers in the diagnosis of ovarian cancer: a systematic review with meta-analysis. Expert Review of Molecular Diagnostics, 2015, 15, 829-852.	3.1	30
31	Autoantibodies to tumor-associated antigens as biomarkers in human hepatocellular carcinoma (HCC). Experimental Hematology and Oncology, 2013, 2, 15.	5.0	29
32	Overexpression of p62/IMP2 can Promote Cell Migration in Hepatocellular Carcinoma via Activation of the Wnt/Î²-Catenin Pathway. Cancers, 2020, 12, 7.	3.7	29
33	Identification of glutathione S-transferase omega 1 (GSTO1) protein as a novel tumor-associated antigen and its autoantibody in human esophageal squamous cell carcinoma. Tumor Biology, 2014, 35, 10871-10877.	1.8	28
34	Preferential Autoimmune Response in Prostate Cancer to Cyclin B1 in a Panel of Tumor-Associated Antigens. Journal of Immunology Research, 2014, 2014, 1-9.	2.2	28
35	Serum anti-MDM2 and anti-c-Myc autoantibodies as biomarkers in the early detection of lung cancer. OncoImmunology, 2016, 5, e1138200.	4.6	28
36	Evaluation of serum autoantibodies against tumor-associated antigens as biomarkers in lung cancer. Tumor Biology, 2017, 39, 101042831771166.	1.8	27

#	Article	IF	Citations
37	Mini-array of multiple tumor-associated antigens to enhance autoantibody detection for immunodiagnosis of hepatocellular carcinoma. Autoimmunity Reviews, 2007, 6, 143-148.	5.8	25
38	CIP2A regulates cell proliferation via the AKT signaling pathway in human lung cancer. Oncology Reports, 2014, 32, 1683-1694.	2.6	25
39	Using Serological Proteome Analysis to Identify Serum Anti-Nucleophosmin 1 Autoantibody as a Potential Biomarker in European-American and African-American Patients With Prostate Cancer. Prostate, 2016, 76, 1375-1386.	2.3	25
40	Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies. Oncology Reports, 2006, 16, 1105.	2.6	24
41	A panel of autoantibodies against multiple tumor-associated antigens in the immunodiagnosis of esophageal squamous cell cancer. Cancer Immunology, Immunotherapy, 2016, 65, 1233-1242.	4.2	24
42	Early detection of hepatocellular carcinoma using autoantibody profiles from a panel of tumor-associated antigens. Cancer Immunology, Immunotherapy, 2018, 67, 835-841.	4.2	22
43	A cancer-related protein 14-3-3Î¶ is a potential tumor-associated antigen in immunodiagnosis of hepatocellular carcinoma. Tumor Biology, 2014, 35, 4247-4256.	1.8	21
44	Overexpression of HCC1/CAPERÎ± may play a role in lung cancer carcinogenesis. Tumor Biology, 2014, 35, 6311-6317.	1.8	21
45	Immunoseroproteomic Profiling in African American Men with Prostate Cancer: Evidence for an Autoantibody Response to Glycolysis and Plasminogen-Associated Proteins. Molecular and Cellular Proteomics, 2016, 15, 3564-3580.	3.8	21
46	MicroRNA-134 prevents the progression of esophageal squamous cell carcinoma via the PLXNA1-mediated MAPK signalling pathway. EBioMedicine, 2019, 46, 66-78.	6.1	21
47	Identification of Tumor-Associated Antigens as Diagnostic and Predictive Biomarkers in Cancer. Methods in Molecular Biology, 2009, 520, 1-10.	0.9	21
48	Detection of autoantibodies to multiple tumor-associated antigens (TAAs) in the immunodiagnosis of breast cancer. Tumor Biology, 2015, 36, 1307-1312.	1.8	20
49	Lysine demethylase LSD1 delivered via small extracellular vesicles promotes gastric cancer cell stemness. EMBO Reports, 2021, 22, e50922.	4.5	20
50	Analyses of autoantibodies against tumor-associated antigens in patients with hepatocellular carcinoma. International Journal of Oncology, 2005, 27, 1079-85.	3.3	20
51	Significance of autoantibodies against insulin-like growth factor II mRNA-binding proteins in patients with hepatocellular carcinoma. International Journal of Oncology, 2005, 26, 311-7.	3.3	19
52	Autoantibody responses in Chinese hepatocellular carcinoma. Journal of Clinical Immunology, 2002, 22, 98-105.	3.8	18
53	Analyses of autoantibodies against tumor-associated antigens in patients with hepatocellular carcinoma. International Journal of Oncology, 2005, 27, 1079.	3.3	18
54	Immunodiagnostic Biomarkers for Hepatocellular Carcinoma (HCC): The First Step in Detection and Treatment. International Journal of Molecular Sciences, 2021, 22, 6139.	4.1	18

#	Article	IF	Citations
55	Autoantibody response to a novel tumor-associated antigen p90/CIP2A in breast cancer immunodiagnosis. Tumor Biology, 2014, 35, 2661-2667.	1.8	16
56	Serum autoantibodies against a panel of 15 tumor-associated antigens in the detection of ovarian cancer. Tumor Biology, 2017, 39, 101042831769913.	1.8	16
57	Detection of autoantibodies to multiple tumor-associated antigens in the immunodiagnosis of ovarian cancer. Molecular Medicine Reports, 2008, 1, 589-94.	2.4	16
58	Mini-Array of Multiple Tumor-associated Antigens (TAAs) in the Immunodiagnosis of Esophageal Cancer. Asian Pacific Journal of Cancer Prevention, 2014, 15, 2635-2640.	1.2	15
59	CIP2A regulates cancer metabolism and CREB phosphorylation in non-small cell lung cancer. Molecular BioSystems, 2015, 11, 105-114.	2.9	14
60	Evaluation and characterization of anti-RalA autoantibody as a potential serum biomarker in human prostate cancer. Oncotarget, 2016, 7, 43546-43556.	1.8	14
61	Autoantibodies to Ca2+ binding protein Calnuc is a potential marker in colon cancer detection. International Journal of Oncology, 2007, , .	3.3	13
62	Tumor-associated antigen CAPERÎ± and microvessel density in hepatocellular carcinoma. Oncotarget, 2016, 7, 16985-16995.	1.8	13
63	Significance of autoantibodies against insulin-like growth factor II mRNA-binding proteins in patients with hepatocellular carcinoma. International Journal of Oncology, 2005, 26, 311.	3.3	12
64	Humoral Autoimmune Responses to Insulin-Like Growth Factor II mRNA-Binding Proteins IMP1 and p62/IMP2 in Ovarian Cancer. Journal of Immunology Research, 2014, 2014, 1-7.	2.2	12
65	Genetic variant of cyclooxygenase-2 in gastric cancer: More inflammation and susceptibility. World Journal of Gastroenterology, 2021, 27, 4653-4666.	3.3	12
66	Association of Polymorphisms in X-Ray Repair Cross Complementing 1 Gene and Risk of Esophageal Squamous Cell Carcinoma in a Chinese Population. BioMed Research International, 2015, 2015, 1-7.	1.9	10
67	Humoral autoimmune response to nucleophosmin in the immunodiagnosis of hepatocellular carcinoma. Oncology Reports, 2015, 33, 2245-52.	2.6	10
68	Discovery of vanoxerine dihydrochloride as a CDK2/4/6 triple-inhibitor for the treatment of human hepatocellular carcinoma. Molecular Medicine, 2021, 27, 15.	4.4	10
69	Proteomic-based identification of HSP70 as a tumor-associated antigen in ovarian cancer. Oncology Reports, 2017, 37, 2771-2778.	2.6	9
70	Regulation of MicroRNA-497-Targeting AKT2 Influences Tumor Growth and Chemoresistance to Cisplatin in Lung Cancer. Frontiers in Cell and Developmental Biology, 2020, 8, 840.	3.7	9
71	Autoantibody Response to Murine Double Minute 2 Protein in Immunodiagnosis of Hepatocellular Carcinoma. Journal of Immunology Research, 2014, 2014, 1-10.	2.2	8
72	Autoantibody response to Sui1 and its tissue-specific expression in hepatocellular carcinoma. Tumor Biology, 2016, 37, 2547-2553.	1.8	8

#	Article	IF	Citations
73	Identification of 14â€“3-3Î¶ as a potential biomarker in gastric cancer by proteomics-based analysis. Molecular Medicine Reports, 2017, 16, 7759-7765.	2.4	8
74	Restricted Boltzmann Machines for Classification of Hepatocellular Carcinoma. Computational Biology Journal, 2014, 2014, 1-5.	0.6	7
75	Discovery of a New CDK4/6 and PI3K/AKT Multiple Kinase Inhibitor Aminoquinol for the Treatment of Hepatocellular Carcinoma. Frontiers in Pharmacology, 2021, 12, 691769.	3.5	5
76	Autoantibody to GNAS in Early Detection of Hepatocellular Carcinoma: A Large-Scale Sample Study Combined with Verification in Serial Sera from HCC Patients. Biomedicines, 2022, 10, 97.	3.2	3
77	Immunoseroproteomic profiling in autoantibody to ENO1 as potential biomarker in immunodiagnosis of osteosarcoma by serological proteome analysis (SERPA) approach. OncoImmunology, 2021, 10, .	4.6	2
78	Biotherapy for Autoimmune Liver Diseases. Current Pharmaceutical Biotechnology, 2014, 15, 510-515.	1.6	2